WO2013049152A3 - Methods for evaluating lung cancer status - Google Patents

Methods for evaluating lung cancer status Download PDF

Info

Publication number
WO2013049152A3
WO2013049152A3 PCT/US2012/057263 US2012057263W WO2013049152A3 WO 2013049152 A3 WO2013049152 A3 WO 2013049152A3 US 2012057263 W US2012057263 W US 2012057263W WO 2013049152 A3 WO2013049152 A3 WO 2013049152A3
Authority
WO
WIPO (PCT)
Prior art keywords
lung cancer
methods
cancer status
aspects
evaluating lung
Prior art date
Application number
PCT/US2012/057263
Other languages
French (fr)
Other versions
WO2013049152A2 (en
Inventor
Duncan H. Whitney
Original Assignee
Allegro Diagnostics Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allegro Diagnostics Corp. filed Critical Allegro Diagnostics Corp.
Publication of WO2013049152A2 publication Critical patent/WO2013049152A2/en
Publication of WO2013049152A3 publication Critical patent/WO2013049152A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention in some aspects provides methods of determining the likelihood that a subject has lung cancer based on the expression of informative-genes. In other aspects, the invention provides methods for determining an appropriate diagnostic intervention plan for a subject based on the expression of informative-genes. Related compositions and kits are provided in other aspects of the invention.
PCT/US2012/057263 2011-09-26 2012-09-26 Methods for evaluating lung cancer status WO2013049152A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161539472P 2011-09-26 2011-09-26
US61/539,472 2011-09-26

Publications (2)

Publication Number Publication Date
WO2013049152A2 WO2013049152A2 (en) 2013-04-04
WO2013049152A3 true WO2013049152A3 (en) 2013-07-18

Family

ID=47996714

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/057263 WO2013049152A2 (en) 2011-09-26 2012-09-26 Methods for evaluating lung cancer status

Country Status (1)

Country Link
WO (1) WO2013049152A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2360278A1 (en) 2005-04-14 2011-08-24 Trustees Of Boston University Diagnostic for lung disorders using class prediction
WO2009039457A1 (en) 2007-09-19 2009-03-26 The Trustees Of Boston University Identification of novel pathways for drug development for lung disease
EP3626308A1 (en) 2013-03-14 2020-03-25 Veracyte, Inc. Methods for evaluating copd status
US20170335396A1 (en) 2014-11-05 2017-11-23 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
WO2017197335A1 (en) * 2016-05-12 2017-11-16 Trustees Of Boston University Nasal epithelium gene expression signature and classifier for the prediction of lung cancer
US10927417B2 (en) 2016-07-08 2021-02-23 Trustees Of Boston University Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions
EP3571212B1 (en) * 2017-01-23 2024-03-06 Trustees of Boston University Methods relating to lung cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060252057A1 (en) * 2004-11-30 2006-11-09 Mitch Raponi Lung cancer prognostics
US20110217717A1 (en) * 2006-03-09 2011-09-08 Brody Jerome S Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
US20110224313A1 (en) * 2008-06-05 2011-09-15 British Columbia Cancer Agency Branch Compositions and methods for classifying lung cancer and prognosing lung cancer survival

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060252057A1 (en) * 2004-11-30 2006-11-09 Mitch Raponi Lung cancer prognostics
US20110217717A1 (en) * 2006-03-09 2011-09-08 Brody Jerome S Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
US20110224313A1 (en) * 2008-06-05 2011-09-15 British Columbia Cancer Agency Branch Compositions and methods for classifying lung cancer and prognosing lung cancer survival

Also Published As

Publication number Publication date
WO2013049152A2 (en) 2013-04-04

Similar Documents

Publication Publication Date Title
WO2013163568A3 (en) Methods for evaluating lung cancer status
IL257330B (en) Compositions, methods and kits for diagnosis of lung cancer
WO2013049152A3 (en) Methods for evaluating lung cancer status
MX340453B (en) Biomarkers for lung cancer.
WO2014187959A3 (en) Lung cancer diagnostic method and means
WO2014160499A3 (en) Methods and compositions for detecting pancreatic cancer
WO2012106385A3 (en) Methods of identifying multiple epitopes in cells
CR20150046A (en) ANTI-CD79B ANTIBODIES AND IMMUNOCATE PLAYERS
PH12014501108A1 (en) Anti-il-36r antibodies
WO2012166626A8 (en) Reagents and methods for treating dental disease
WO2014031859A3 (en) Compositions and methods relating to blood-based biomarkers of breast cancer
WO2012135340A3 (en) Compositions and methods for diagnosing cancer
WO2013130963A8 (en) Compositions and methods for treating type iii gaucher disease
WO2013040251A3 (en) Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
WO2013023151A3 (en) Compositions and methods for treating celiac sprue disease
EP3045911A4 (en) Apparatus for manufacturing diagnosis kit, and diagnosis kit manufactured by same
EP2694667A4 (en) Methods, compositions and kits for assaying mitochondrial function
EP3256859A4 (en) A biomarker for diagnosing vascular diseases and the uses thereof
EP2720866A4 (en) Partially opaque-partially clear laminates and methods thereof.
WO2013082249A3 (en) Compositions and methods for prostate cancer analysis
WO2014043633A8 (en) Use of e-cadherin and vimentin for selection of treatment responsive patients
WO2012167163A3 (en) Methods and compositions for detecting endometrial or ovarian cancer
WO2012164525A3 (en) Aging biomarkers
WO2012106680A3 (en) Methods and compositions for chemical drying producing struvite
WO2013166153A3 (en) Methods and compositions for cancer diagnosis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12835959

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12835959

Country of ref document: EP

Kind code of ref document: A2